Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.

Trial Details

NCT ID

NCT03356782

Phase

PHASE1 / PHASE2

Sponsor

Shenzhen Geno-Immune Medical Institute

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

Sarcoma-specific CAR-T cells

Locations (sample)

Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients;
Age: ≥ 18 and ≤65 years of age at the time of enrollment;
At least 4 weeks since any chemotherapy or radiotherapy and at least 1 week since immunosuppressive therapy such as using steroid hormone before en…
Side effects of chemotherapy have been well managed;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →